Get the Stockscreener App
16.99
0.82%
-0.14
Pre-market:
17.01
0.02
+0.12%
Pulse Biosciences Inc stock is traded at $16.99, with a volume of 90,247.
It is down -0.82% in the last 24 hours and down -20.64% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
See More
Previous Close:
$17.13
Open:
$17.27
24h Volume:
90,247
Relative Volume:
0.58
Market Cap:
$1.04B
Revenue:
-
Net Income/Loss:
$-46.13M
P/E Ratio:
-20.92
EPS:
-0.8123
Net Cash Flow:
$-34.10M
1W Performance:
+0.41%
1M Performance:
-20.64%
6M Performance:
-8.21%
1Y Performance:
+58.19%
1-Day Range:
$16.87
$17.89
1-Week Range:
$16.48
$17.91
52-Week Range:
$6.595
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
16.99 | 1.04B | 0 | -46.13M | -34.10M | -0.8123 |
|
ISRG
Intuitive Surgical Inc
|
476.78 | 170.05B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.79 | 63.97B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
86.81 | 42.94B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.72 | 32.28B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.55 | 17.64B | 17.28B | 108.00M | 391.00M | 0.20 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Oppenheimer & Co. Inc. Acquires New Shares in Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 - Bluefield Daily Telegraph
When Will Pulse Biosciences Report Q4 Earnings? Key Date for nsPFA Technology Leader - StockTitan
Pulse Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Pulse Biosciences at TD Cowen Conference: nsPFA Technology Focus By Investing.com - Investing.com Canada
New York State Common Retirement Fund Sells 3,600 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
(PLSE) Trading Signals - Stock Traders Daily
Commit To Purchase Pulse Biosciences At $10, Earn 12.9% Annualized Using Options - Nasdaq
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Joplin Globe
Is Pulse Biosciences' Hiring Spree a Signal for Investors? 165,300 New Stock Options Granted - StockTitan
MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Investor Network: Pulse Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Jon Skinner Hired to Manage Pulse Biosciences Finances - MPO-mag
Pulse Biosciences Releases Nanosecond PFA Catheter Study Results - MPO-mag
Learn to Evaluate (PLSE) using the Charts - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Trading Down 7.8%Here's Why - MarketBeat
Can Pulse Biosciences' Novel Ablation Technology Disrupt Medical Device Market? Key Presentation Coming - StockTitan
Where are the Opportunities in (PLSE) - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.6%Here's What Happened - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month HighShould You Buy? - MarketBeat
Pulse Biosciences Appoints Jon Skinner as Chief Financial Officer - Defense World
Pulse Biosciences names new CFO, continuing string of C-suite changes - MedTech Dive
Pulse Biosciences names Jon Skinner as new CFO By Investing.com - Investing.com South Africa
Pulse Biosciences names Jon Skinner as new CFO - Investing.com India
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer - BioSpace
Pulse Biosciences has a new CFO - Mass Device
Pulse Biosciences Strengthens Leadership with New CFO Appointment - TipRanks
Pulse Biosciences Names Jon Skinner CFO -February 04, 2025 at 08:54 am EST - Marketscreener.com
Pulse Biosciences Appoints Jon Skinner As CFO; Stock Up In Pre-market - Nasdaq
Pulse Biosciences Names Jon Skinner Chief Financial Officer - MarketWatch
Healthcare M&A Expert Takes CFO Role at Pulse Biosciences with $5B Growth Vision - StockTitan
Pulse Biosciences (NASDAQ:PLSE) Trading Up 7.6%Time to Buy? - MarketBeat
Griffin Asset Management Inc. Sells 19,902 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - MarketBeat
(PLSE) Technical Pivots with Risk Controls - Stock Traders Daily
Pulse Biosciences’ Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting - BioSpace
Pulse Biosciences reports successful AF treatment in study - MSN
Pulse Biosciences announces presentation of late-breaking data on nsPFA 360-degree cardiac catheter system - Cardiac Rhythm News
Pulse Biosciences (NASDAQ:PLSE) Shares Up 5.2%Here's What Happened - MarketBeat
Pulse Biosciences touts positive results from PFA early feasibility study - Yahoo Finance
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium - Business Wire
Pulse Biosciences' Cardiac Catheter Shows 92% Success Rate in Atrial Fibrillation Study - StockTitan
Barclays PLC Grows Position in Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
Dec 13 '24 |
Buy |
17.18 |
55,256 |
949,298 |
42,328,717 |
| DUGGAN ROBERT W | Director |
Dec 12 '24 |
Buy |
17.13 |
45,404 |
777,771 |
42,273,461 |
| DUGGAN ROBERT W | Director |
Dec 11 '24 |
Buy |
17.35 |
56,054 |
972,344 |
42,228,057 |
| Barrett Burke Thomas | President and CEO |
May 20 '24 |
Buy |
8.56 |
10,000 |
85,600 |
10,000 |
2.47%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):